These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30227098)

  • 1. The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.
    Lozda R
    Ther Innov Regul Sci; 2017 Nov; 51(6):751-755. PubMed ID: 30227098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On improvement of the mechanism for establishing and changing indicators of quality and food safety in the regulatory and legal acts of the Eurasian Economical Union].
    Arnautov OV
    Vopr Pitan; 2016; 85(1):110-6. PubMed ID: 27228709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The characteristics of regulation of pharmaceutical market of the Eurasian Economical Union].
    Marseva TG; Voblaia IN; Seifieva EN
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2019 Sep; 27(5):841-846. PubMed ID: 31765534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory System Changes in Russia: A Historical Review and Future Perspectives.
    Lozda R
    Ther Innov Regul Sci; 2016 Jul; 50(4):414-418. PubMed ID: 30227015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [TOPICAL ISSUES OF FUNCTIONING AND DEVELOPMENT OF THE SINGLE MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION].
    Tonkonog VV; Ananchenkova PI; Shimanovskyi NL; Vrubel ME
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Oct; 31(Special Issue 2):1268-1274. PubMed ID: 38069897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The issues of development and functioning of common market of medical equipment and articles within the framework of the Eurasian Economic Union].
    Tonkonog VV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2024 Jul; 32(4):778-784. PubMed ID: 39158875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market power in the United States red meatpacking industry.
    Koontz SR
    Vet Clin North Am Food Anim Pract; 2003 Jul; 19(2):519-44. PubMed ID: 12951745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Community requirements relating to drugs derived from human blood and plasma].
    Brunko P
    Ann Pharm Fr; 1994; 52(2):89-98. PubMed ID: 7944184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The State and Prospects of Russia's Agri-Food Export to the Countries of the Eurasian Economic Union.
    Kiselev SV; Romashkin RA
    Stud Russ Econ Dev; 2021; 32(2):221-228. PubMed ID: 33976528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of immunological veterinary medicinal products in the European Union.
    Brunko P
    Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drugs in the European Union: the health-market complex].
    Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
    Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.